IL6 and rheumatoid arthritis: Choy et al. reported that IL-6 blockade with tocilizumab significantly reduced systemic inflammation and disease activity in rheumatoid arthritis, underscoring the feasibility of targeting this pathway in chronic inflammatory conditions [41].